Ever since last summer, when Lynn Gemmell’s dog, Bela, was inducted into the trial of a drug that has been shown to significantly lengthen the lives of laboratory mice, she has been the object of intense scrutiny among dog park regulars.
To those who insist that Bela, 8, has turned back into a puppy — “Look how fast she’s getting that ball!” — Ms. Gemmell has tried to turn a deaf ear. Bela, a Border collie-Australian shepherd mix, may have been given a placebo, for one thing.
The drug, rapamycin, which improved heart health and appeared to delay the onset of some diseases in older mice, may not work the same magic in dogs, for another. There is also a chance it could do more harm than good. “This is just to look for side effects, in dogs,” Ms. Gemmell told Bela’s many well-wishers.
Technically that is true. But the trial also represents a new frontier in testing a proposition for improving human health: Rather than only seeking treatments for the individual maladies that come with age, we might do better to target the biology that underlies aging itself.
While the diseases that now kill most people in developed nations — heart disease, stroke, Alzheimer’s, diabetes, cancer — have different immediate causes, age is the major risk factor for all of them. That means that even treatment breakthroughs in these areas, no matter how vital to individuals, would yield on average four or five more years of life, epidemiologists say, and some of them likely shadowed by illness.
A drug that slows aging, the logic goes, might instead serve to delay the onset of several major diseases at once. A handful of drugs tested by federally funded laboratories in recent years appear to extend the healthy lives of mice, with rapamycin and its derivatives, approved by the Food and Drug Administration for organ transplant patients and to treat some types of cancer, so far proving the most effective. In a 2014 study by the drug company Novartis, the drug appeared to bolster the immune system in older patients. And the early results in aging dogs suggest that rapamycin is helping them, too, said Matt Kaeberlein, a biology of aging researcher at the University of Washington who is running the study with a colleague, Daniel Promislow.
But scientists who champion the study of aging’s basic biology — they call it “geroscience” — say their field has received short shrift from the biomedical establishment. And it was not lost on the University of Washington researchers that exposing dog lovers to the idea that aging could be delayed might generate popular support in addition to new data.
“Many of us in the biology of aging field feel like it is underfunded relative to the potential impact on human health this could have,” said Dr. Kaeberlein, who helped pay for the study with funds he received from the university for turning down a competing job offer. “If the average pet owner sees there’s a way to significantly delay aging in their pet, maybe it will begin to impact policy decisions.”
The Latest on: Geroscience
via Google News
The Latest on: Geroscience
- OU College of Medicine receives $10.7 million grant for geroscience research on February 11, 2019 at 8:19 am
OKLAHOMA CITY - To advance research in the field of geroscience - which studies the relationship between aging and disease - the University of Oklahoma College of Medicine has been awarded a $10.7 ... […]
- Mayo Clinic Working Towards Accelerating the Pace Aging Research on December 31, 2018 at 10:47 am
Recent research suggests that aging may actually be a modifiable risk factor. Mayo Clinic, along with other members of the Geroscience Network, has published six manuscripts that map strategies for ... […]
- China to boost geroscience research on December 15, 2018 at 6:01 pm
China will boost its geroscience research and develop more geroscience-related academic disciplines to respond to its ageing population, according to a symposium Saturday. The country will explore the ... […]
- China to boost geroscience research on December 15, 2018 at 4:17 am
BEIJING, Dec. 15 (Xinhua) -- China will boost its geroscience research and develop more geroscience-related academic disciplines to respond to its ageing population, according to a symposium Saturday. ... […]
- Rush of research, investment in human longevity comes to San Francisco Bay Area on December 13, 2018 at 10:44 am
Geroscience, a term coined at Buck in 2007, is based on the recognition that aging itself is the enabler of the deadly and debilitating afflictions associated with growing old: Alzheimer’s, heart ... […]
- Buck Institute in Novato marks 30 years of aging research on December 3, 2018 at 7:28 pm
“Think about it as a punctuation mark,” said Eric Verdin, president and CEO of the geroscience center. “Aging research has been done for 30 years now. The Buck was founded about 10 years into this.” ... […]
- Aging As A Biological Target on October 1, 2018 at 12:43 am
There is abundant evidence in animal models of the geroscience hypothesis linking these biological discoveries to human health by proposing targeting biological aging processes can prevent or a ... […]
- Geroscience takes center stage in Journal of the American Medical Association on September 20, 2018 at 12:15 am
Geroscience--the burgeoning research field that focuses on the genetic, molecular, and cellular mechanisms that make aging a major risk factor for most chronic diseases as we age--takes center stage ... […]
- Journal of the American Medical Association shines spotlight on geroscience on September 19, 2018 at 9:19 am
September 18, 2018 (New York, NY) - Geroscience--the burgeoning research field that focuses on the genetic, molecular, and cellular mechanisms that make aging a major risk factor for most chronic ... […]
- Scientists in Mass. and beyond are working to slow the aging process on May 19, 2018 at 4:25 pm
These approaches and others are part of an emerging field known as geroscience. Its advocates believe that the best way to treat a variety of illnesses — from cancers and heart disease to Alzheimer’s ... […]
via Bing News